TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00016523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Started at 5 ppm and could be increased to 10 ppm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Started at 5 ppm and could be increased to 10 ppm
Study: NCT03696043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVD placement
Description: A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EVD placement
Description: A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
Study: NCT04799223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four-foods eating guidelines
Description: To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No designed-foods eating guidelines
Description: To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
Study: NCT05655429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic partial meniscectomy
Description: Arthroscopic partial meniscectomy surgery procedure
Study: NCT01288924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: NSS 2 ml intravenous before surgery and every 12 hours for two days.
Study: NCT03776929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy
Description: Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
Study: NCT02936505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily.
Study: NCT04428905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05798338

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Analysis of plasma in order to quantify and characterize EVs

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Analysis of plasma in order to quantify and characterize EVs

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Analysis of plasma in order to quantify and characterize EVs
Study: NCT04428905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04763096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks.
Study: NCT01304979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapies
Description: Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Indirect therapies that mimic direct therapy intervention
Study: NCT02370836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
Study: NCT01927991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT (internet-based, cognitive-behavioural therapy)
Description: The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCBT (internet-based, cognitive-behavioural therapy)
Description: The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
Study: NCT03059329

Intervention type: DRUG
Intervention: Fycompa
Description: The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
Study: NCT04987749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study: NCT04345016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Once-daily remote foot temperature monitoring
Description: Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
Study: NCT00564187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Study: NCT00172016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT02261220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is administered by IV infusion in combination with tremelimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab is administered by IV infusion in combination with MEDI4736
Study: NCT02907073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF4
Description: Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF4
Description: Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF4
Description: Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
Study: NCT02071368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
Study: NCT02936505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Anti thymocyte globulin
Description: Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti thymocyte globulin
Description: Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months.
Study: NCT02071368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 150 mg/500
Description: Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Description: Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
Study: NCT02178124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03749915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Ease Cold Spray
Description: Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ametop
Description: Tetracaine Hydrochloride Gel 4%
Study: NCT00199901

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NY-ESO-1 ISCOMATRIX®
Description: 100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ISCOMATRIX® adjuvant
Description: 120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).
Study: NCT02339740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV
Study: NCT00645723

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colistin and saline solution
Description: intravenous colistin and nebulized saline solution
Study: NCT02339740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study: NCT02936505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: * Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily.
Study: NCT04180059

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CTL 19
Description: Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
Study: NCT04099316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional resistance exercise
Description: Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
Study: NCT03216551

Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-operative frozen section
Description: Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
Study: NCT03516292

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Nerve Growth Factor
Description: The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Nerve Growth Factor
Description: The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
Study: NCT03642015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: listening the music 15 min
Study: NCT02554942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
Study: NCT02422173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: The active electrode is placed on the affected hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Description: The active electrode is placed on the unaffected hemisphere

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral transcranial direct current stimulation
Description: The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Placebo stimulation, with emission current by only 30 seconds
Study: NCT00507091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 100mg
Description: once daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 300mg
Description: once daily oral tablet
Study: NCT01841658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
Study: NCT01872221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol
Study: NCT03729466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pilates
Description: The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
Study: NCT01262261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
Study: NCT04990245

Intervention type: DIAGNOSTIC_TEST
Intervention: endoscopic biopsies
Description: patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
Study: NCT02339740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT04428905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02339740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO